Summit Therapeutics (SMMT) Tops Q1 EPS by 4c

Summit Therapeutics (NASDAQ: SMMT) reported Q1 EPS of (GBP0.24), GBP0.04 better than the analyst estimate of (GBP0.28).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Ericsson (ERIC) Tops Q2 EPS by 3c
• Barclays Downgrades Equity Residential (EQR) to Equalweight
• USA Today (TDAY) PT Raised to $10 at Citizens as In-Line Results Expected